A recent report published by
Infinium Global Research on the artemisinin combination therapy market provides
in-depth analysis of segments and sub-segments in the global as well as
regional artemisinin combination therapy market. The study also highlights the
impact of drivers, restraints, and macro indicators on the global and regional
artemisinin combination therapy market over the short term as well as long term.
The report is a comprehensive presentation of trends, forecast and dollar
values of the global artemisinin combination therapy market. According to the
report, the global artemisinin combination therapy market is projected to grow
at a CAGR of 8% over the forecast period of 2021-2027.
The revenue generated by the
market was approximately USD 512 million in 2021 and is expected to reach
approximately USD 829 million in 2027. Artemisinin is a derivative of plant
extracted from Artemisia annua, that has been shown to reduce the amount of
plasmodium parasites in malaria patients' blood effectively and quickly. For
uncomplicated falciparum malaria, artemisinin-based combination therapies
(ACTs) are now widely regarded as the most effective treatment. They work
quickly and consistently. Artemisinin Combination Therapy became the first line
of treatment as sulfadoxine–pyrimethamine and chloroquine became ineffective
and non-lethal as falciparum malaria bacteria developed a resistance towards
these drugs. Even World Health Organization has classified Artemisinin
Combination Therapy as the primary treatment of uncomplicated falciparum
malaria. The Artemisinin Combination Therapy types are Artesunate-Amodiaquine,
Artesunate-Mefloquine and can be accessed through hospitals, clinics,
pharmacies and other distribution channels.
According to WHO there were around
241 million cases of malaria around the world in 2020. In 2020, the number of
deaths due to malaria were 627,000. Also, WHO mentioned that out of 241 million
cases 95% of cases belonged to Africa and over 96% of malaria deaths.
Artemisinin Combination Therapy provides a safe and effective way of curing
malaria in these under-developing countries. Therefore, Prevalence of malaria
in under-developing countries is propelling the growth of the market. The
accessibility to Artemisinin Combination Therapy is also growing due to
improvement in healthcare infrastructure in under-developing countries.
International organizations such as WHO, World Bank and others are sending aids
and funding healthcare infrastructure projects in under-developing countries
which is expected to significantly increases the access of people to healthcare
infrastructure such as hospitals and clinics. This factor is expected to aid
the growth of the market. The Artemisinin Combination Therapy are costly which
is expected to restrain the growth of the market. Nevertheless, new
opportunities are expected to arise as the research and development for new
combination therapies of Artemisinin is growing.
The Artemisinin Combination
Therapy market is segmented region wise into North America, Europe, Asia-Pacific
and Rest of the World. Asia-Pacific is expected to be the biggest market region
wise. In 2020, Africa had over 96% of total malaria cases in the world
according to World Health Organization. The widespread prevalence is the major
factor responsible for the strong growth of the market in Africa. Other factors
supporting the growth of the market are the growing income level of people and
growing accessibility to Artemisinin Combination Therapy.
The report on global artemisinin
combination therapy market covers segments such as therapy type, and
distribution channel. On the basis of therapy type, the sub-markets include
dihydroartemisinin-piperaquine, artesunate-sulfadoxine-pyrimethamine, pyronaridine-artesunate,
and artesunate-mefloquine. On the basis of distribution channel, the
sub-markets include hospitals, clinics and pharmacies, retail and drug stores,
The report provides profiles of
the companies in the market such as Novartis AG, Cipla Ltd, Sanofi SA, Desano
Holdings Ltd., KPC Pharmaceuticals Inc., Guilin Pharmaceuticals, Calyx
Chemicals and Pharmaceuticals Ltd., DENK PHARMA GmbH & Co. KG, Mylan N.V., and
Hovid Berhad .
The report provides deep insights
into the demand forecasts, market trends, and micro and macro indicators. In
addition, this report provides insights into the factors that are driving and
restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis
given in the report brings an insight into the investment areas that existing
or new market players can consider. The report provides insights into the
market using analytical tools such as Porter's five forces analysis and DRO
analysis of artemisinin combination therapy market. Moreover, the study
highlights current market trends and provides forecast from 2021-2027. We also
have highlighted future trends in the market that will affect the demand during
the forecast period. Moreover, the competitive analysis given in each regional
market brings an insight into the market share of the leading players.